Skip to main content

Table 7 Descriptive statistics for aggregated company-level payments reported by companies following the ABPI Code (2018)

From: International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency

Payment categories

Minimum ($)

Median (IQR) ($)

Maximum ($)

All aggregated payments

 Value

0.0

164,675.9 (10,975.9—1,674,936.9)

48,451,656.3

 Share of all payments

0.0%

60.2% (19.2%—80.4%)

100.0%

Aggregated non-R&D payments

 Value

0.0

35,417.6 (1,700.9—145,195.9)

1,468,816.7

 Share of all payments

0.0%

5.5% (1.1%—16.4%)

100.0%

 Share of all aggregated payments

0.0%

20.1% (3.8%—100%)

100%

Aggregated non-R&D payments to HCPs

 Value

0.0

34,623.5 (1,700.9—145,195.9)

1,468,816.7

 Share of payments to HCPs

0.0%

49.7% (14.7%—77.1%)

100.0%

 Share of aggregated non-R&D payments

0.0%

100.0% (100.0%—100.0%)

100.0%

R&D payments

 Value

0.0

92,443.7 (0—1,615,243.1)

47,430,167.7

 Share of all payments

0.0%

43.6% (0 – 73.3%)

100.0%

 Share of all aggregated payments

0.0%

79.9% (0%—96.2%)

100.0%

  1. Aggregated payments Payments without named recipients, HCPs Healthcare professionals, HCOs Healthcare organisations, R&D Research and development